Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewISOX INACT is a negative control for PF CBP1. Exhibits negligible activity at CBP and BRD4.
Active Analog also available.
Sold for research purposes under agreement from Pfizer Inc.
分子量 | 488.62 |
公式 | C29H36N4O3 |
储存 | Store at +4°C |
纯度 | ≥98% (HPLC) |
PubChem ID | 121237856 |
InChI Key | FTOHXUPHICJSCR-UHFFFAOYSA-N |
Smiles | CC(ON=C1C)=C1C2=C(C)C(N=C(CCC3=CC=C(OC)C=C3)N4CCN5CCOCC5)=C4C=C2C |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
参考文献是支持产品生物活性的出版物。
Chekler et al (2015) Transcriptional profiling of a selective CREB binding protein bromodomain inhibitor highlights therapeutic opportunities. Chem.Biol. 22 1588 PMID: 26670081
关键词: ISOX INACT, ISOX INACT supplier, ISOXINACT, negative, control, PFCBP1, bromodomains, CBP, BRD4, Bromodomains, 5808, Tocris Bioscience
目前没有该产品的评论。 Be the first to review ISOX INACT and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.